IN2014DN11269A - - Google Patents
Info
- Publication number
- IN2014DN11269A IN2014DN11269A IN11269DEN2014A IN2014DN11269A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A IN 11269DEN2014 A IN11269DEN2014 A IN 11269DEN2014A IN 2014DN11269 A IN2014DN11269 A IN 2014DN11269A
- Authority
- IN
- India
- Prior art keywords
- cell
- malignant cancers
- cell malignant
- lymphoma
- cancers include
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 230000003211 malignant effect Effects 0.000 abstract 4
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 abstract 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261663885P | 2012-06-25 | 2012-06-25 | |
| US201261670918P | 2012-07-12 | 2012-07-12 | |
| PCT/EP2013/063313 WO2014001356A1 (en) | 2012-06-25 | 2013-06-25 | Method of treating lymphoma using thienotriazolodiazepine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN11269A true IN2014DN11269A (enrdf_load_stackoverflow) | 2015-10-09 |
Family
ID=48672651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN11269DEN2014 IN2014DN11269A (enrdf_load_stackoverflow) | 2012-06-25 | 2013-06-25 |
Country Status (12)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| SG11201506924YA (en) | 2013-03-15 | 2015-09-29 | Incyte Corp | Tricyclic heterocycles as bet protein inhibitors |
| US9290514B2 (en) | 2013-07-08 | 2016-03-22 | Incyte Holdings Corporation | Tricyclic heterocycles as BET protein inhibitors |
| KR20160036591A (ko) * | 2013-08-01 | 2016-04-04 | 온코에틱스 게엠베하 | 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 제제 |
| WO2015018520A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma |
| WO2015018522A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl) |
| WO2015018521A1 (en) * | 2013-08-06 | 2015-02-12 | Oncoethix Sa | Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| JP2016538310A (ja) * | 2013-11-27 | 2016-12-08 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を含む医薬製剤を用いる白血病の治療方法 |
| WO2015095492A1 (en) | 2013-12-19 | 2015-06-25 | Incyte Corporation | Tricyclic heterocycles as bet protein inhibitors |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| TWI672301B (zh) | 2014-04-23 | 2019-09-21 | 美商英塞特公司 | 作為ＢＥＴ蛋白抑制劑之１Ｈ-吡咯并［２，３-ｃ］吡啶-７（６Ｈ）-酮及吡唑并［３，４-ｃ］吡啶-７（６Ｈ）-酮 |
| US9956228B2 (en) | 2014-05-02 | 2018-05-01 | Oncoethix Gmbh | Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds |
| CA2947593A1 (en) * | 2014-05-02 | 2015-11-05 | Oncoethix Gmbh | Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds |
| EP3139959A1 (en) | 2014-05-08 | 2017-03-15 | Oncoethix GmbH | Method of treating triple-negative breast cancer using thienotriazolodiazepine compounds |
| EP3154549A1 (en) | 2014-06-13 | 2017-04-19 | Oncoethix GmbH | Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds |
| WO2016026912A1 (en) * | 2014-08-19 | 2016-02-25 | Oncoethix Gmbh | Methods of treating lymphoma using thienotriazolodiazepine compounds |
| WO2016044130A1 (en) | 2014-09-15 | 2016-03-24 | Incyte Corporation | Tricyclic heterocycles for use as bet protein inhibitors |
| KR101675984B1 (ko) | 2015-02-23 | 2016-11-14 | 한양대학교 에리카산학협력단 | 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| EP4414369A3 (en) | 2015-03-18 | 2024-10-16 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| WO2016176335A1 (en) | 2015-04-27 | 2016-11-03 | Concert Pharmaceuticals, Inc. | Deuterated otx-015 |
| WO2017030814A1 (en) | 2015-08-19 | 2017-02-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| AR106520A1 (es) | 2015-10-29 | 2018-01-24 | Incyte Corp | Forma sólida amorfa de un inhibidor de proteína bet |
| CN114369091A (zh) | 2016-06-20 | 2022-04-19 | 因赛特公司 | Bet抑制剂的结晶固体形式 |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| CN108070562A (zh) * | 2018-02-03 | 2018-05-25 | 金华市中心医院 | 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法 |
| MX2020010571A (es) | 2018-04-13 | 2021-01-08 | Arvinas Operations Inc | Ligandos de cereblon y compuestos bifuncionales que los comprenden. |
| EP4342543A3 (en) | 2018-09-11 | 2024-06-19 | F. Hoffmann-La Roche AG | Tert-butyl (s)-2-(4-(phenyl)-6h-thieno[3,2-f][1,2,4]triazolo[4,3-a] [1,4]diazepin-6-yl) acetate derivatives and related compounds as bromodomain brd4 inhibitors for treating cancer |
| CA3165168A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| WO2025049555A1 (en) | 2023-08-31 | 2025-03-06 | Oerth Bio Llc | Compositions and methods for targeted inhibition and degradation of proteins in an insect cell |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994006802A1 (en) | 1992-09-18 | 1994-03-31 | Yoshitomi Pharmaceutical Industries, Ltd. | Thienodiazepine compound and medicinal use thereof |
| CN1109037C (zh) * | 1996-09-13 | 2003-05-21 | 三菱制药株式会社 | 噻吩并－三唑并二氮杂䓬化合物及其医药用途 |
| KR101600634B1 (ko) * | 2007-12-28 | 2016-03-07 | 미쓰비시 타나베 파마 코퍼레이션 | 항암제 |
| JP5715241B2 (ja) * | 2010-05-14 | 2015-05-07 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法 |
| DK2571503T3 (en) * | 2010-05-14 | 2015-04-20 | Dana Farber Cancer Inst Inc | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF NEOPLASIA, INFLAMMATORY DISEASE AND OTHER DISORDERS |
| WO2013033420A1 (en) * | 2011-08-30 | 2013-03-07 | Whitehead Institute For Biomedical Research | Methods of downregulating translocated oncogene expression using bromodomain inhibitors |
-
2013
- 2013-06-25 JP JP2015517810A patent/JP6265979B2/ja not_active Expired - Fee Related
- 2013-06-25 WO PCT/EP2013/063313 patent/WO2014001356A1/en active Application Filing
- 2013-06-25 MX MX2014015986A patent/MX2014015986A/es unknown
- 2013-06-25 BR BR112014032105A patent/BR112014032105A2/pt not_active Application Discontinuation
- 2013-06-25 EP EP13730912.6A patent/EP2863923B1/en not_active Not-in-force
- 2013-06-25 IN IN11269DEN2014 patent/IN2014DN11269A/en unknown
- 2013-06-25 CN CN201380045846.0A patent/CN105050605A/zh active Pending
- 2013-06-25 CA CA2877434A patent/CA2877434A1/en not_active Abandoned
- 2013-06-25 US US13/926,029 patent/US20140018353A1/en not_active Abandoned
- 2013-06-25 KR KR20157000782A patent/KR20150045423A/ko not_active Withdrawn
- 2013-06-25 RU RU2015101106A patent/RU2659171C2/ru not_active IP Right Cessation
- 2013-06-25 AU AU2013283378A patent/AU2013283378B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015531747A (ja) | 2015-11-05 |
| JP6265979B2 (ja) | 2018-01-24 |
| RU2015101106A (ru) | 2016-08-10 |
| KR20150045423A (ko) | 2015-04-28 |
| MX2014015986A (es) | 2016-02-11 |
| EP2863923A1 (en) | 2015-04-29 |
| RU2659171C2 (ru) | 2018-06-28 |
| CA2877434A1 (en) | 2014-01-03 |
| CN105050605A (zh) | 2015-11-11 |
| AU2013283378A1 (en) | 2015-01-29 |
| WO2014001356A1 (en) | 2014-01-03 |
| EP2863923B1 (en) | 2019-05-08 |
| US20140018353A1 (en) | 2014-01-16 |
| BR112014032105A2 (pt) | 2017-08-01 |
| AU2013283378B2 (en) | 2017-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN11269A (enrdf_load_stackoverflow) | ||
| MX2010003815A (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2. | |
| MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| PH12015500940A1 (en) | Bruton`s tyrosine kinase inhibitors | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| NZ726488A (en) | Compositions and methods for transmucosal absorption | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
| MX2011007589A (es) | Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| TN2012000414A1 (en) | Forms of rifaximin and uses thereof | |
| MX2014002668A (es) | Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas. | |
| MX2014004862A (es) | Formulaciones de polimero acrilico. | |
| PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| MX360409B (es) | Terapia de combinacion de dosis fija para la enfermedad de parkinson. | |
| MD4538B1 (ro) | 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei | |
| CL2011002812A1 (es) | Compuestos derivados de [1,2,4]triazolo[4,3-b]piridazinas; proceso de preparacion; y uso en el tratamiento del cancer a la prostata. | |
| MX2011008994A (es) | Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2. | |
| PH12013501115A1 (en) | Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer | |
| WO2012125871A3 (en) | Aconitine compounds, compositions, uses, and preparation thereof | |
| GB2519004A (en) | Quinone compounds and their uses for the treatment of cancer | |
| TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia |